Crispr Therapeutics (NASDAQ:CRSP) had its price objective hoisted by Roth Capital from $65.00 to $100.00 in a report published on Tuesday, November 19th, The Fly reports.
CRSP has been the subject of a number of other research reports. Jefferies Financial Group assumed coverage on Crispr Therapeutics in a research note on Thursday, August 1st. They issued a buy rating and a $64.00 price objective for the company. Wells Fargo & Co reissued a buy rating on shares of Crispr Therapeutics in a report on Tuesday, November 19th. Chardan Capital restated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Oppenheimer upgraded shares of Crispr Therapeutics from a market perform rating to an outperform rating and set a $65.00 price objective for the company in a report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a buy rating and issued a $62.00 target price on shares of Crispr Therapeutics in a research note on Wednesday, July 31st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $69.54.
NASDAQ:CRSP opened at $72.37 on Tuesday. Crispr Therapeutics has a 52 week low of $22.22 and a 52 week high of $74.00. The firm has a 50-day moving average price of $54.81 and a two-hundred day moving average price of $47.38. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, sell-side analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Nikko Asset Management Americas Inc. lifted its position in shares of Crispr Therapeutics by 324.3% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after acquiring an additional 701,332 shares during the period. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the third quarter worth $21,167,000. Price T Rowe Associates Inc. MD grew its position in shares of Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Institutional investors and hedge funds own 49.81% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Consumer behavior in bull markets
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.